JP2025502061A5 - - Google Patents
Info
- Publication number
- JP2025502061A5 JP2025502061A5 JP2024540882A JP2024540882A JP2025502061A5 JP 2025502061 A5 JP2025502061 A5 JP 2025502061A5 JP 2024540882 A JP2024540882 A JP 2024540882A JP 2024540882 A JP2024540882 A JP 2024540882A JP 2025502061 A5 JP2025502061 A5 JP 2025502061A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- muc16
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263297333P | 2022-01-07 | 2022-01-07 | |
| US63/297,333 | 2022-01-07 | ||
| US202263342542P | 2022-05-16 | 2022-05-16 | |
| US63/342,542 | 2022-05-16 | ||
| US202263394483P | 2022-08-02 | 2022-08-02 | |
| US63/394,483 | 2022-08-02 | ||
| US202263421541P | 2022-11-01 | 2022-11-01 | |
| US63/421,541 | 2022-11-01 | ||
| PCT/US2023/010326 WO2023133280A1 (en) | 2022-01-07 | 2023-01-06 | Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025502061A JP2025502061A (ja) | 2025-01-24 |
| JP2025502061A5 true JP2025502061A5 (https=) | 2026-01-13 |
Family
ID=85199214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540882A Pending JP2025502061A (ja) | 2022-01-07 | 2023-01-06 | 再発性卵巣癌を、二重特異性抗ｍｕｃ１６×抗ｃｄ３抗体単独で、または抗ｐｄ－１抗体と組み合わせて治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230312718A1 (https=) |
| EP (1) | EP4460520A1 (https=) |
| JP (1) | JP2025502061A (https=) |
| KR (1) | KR20240130137A (https=) |
| AU (1) | AU2023204751A1 (https=) |
| CA (1) | CA3242629A1 (https=) |
| IL (1) | IL313864A (https=) |
| MX (1) | MX2024008055A (https=) |
| WO (1) | WO2023133280A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7066690B2 (ja) * | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| TW202542187A (zh) * | 2023-12-12 | 2025-11-01 | 美商再生元醫藥公司 | 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| JP7066690B2 (ja) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| TW202504917A (zh) * | 2018-06-21 | 2025-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法 |
-
2023
- 2023-01-06 US US18/094,176 patent/US20230312718A1/en active Pending
- 2023-01-06 CA CA3242629A patent/CA3242629A1/en active Pending
- 2023-01-06 AU AU2023204751A patent/AU2023204751A1/en active Pending
- 2023-01-06 MX MX2024008055A patent/MX2024008055A/es unknown
- 2023-01-06 EP EP23703960.7A patent/EP4460520A1/en active Pending
- 2023-01-06 KR KR1020247026382A patent/KR20240130137A/ko active Pending
- 2023-01-06 IL IL313864A patent/IL313864A/en unknown
- 2023-01-06 WO PCT/US2023/010326 patent/WO2023133280A1/en not_active Ceased
- 2023-01-06 JP JP2024540882A patent/JP2025502061A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI890661B (zh) | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 | |
| EP3986569A1 (en) | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen | |
| JP2023505218A5 (https=) | ||
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| JP2019503361A (ja) | がんを治療するための抗ｐｄ−１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ | |
| CN105377894A (zh) | 以il-4r抑制剂治疗过敏症及强化过敏原特异性免疫治疗的方法 | |
| JP2021528423A5 (https=) | ||
| WO2020063988A1 (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| JP2022512851A5 (https=) | ||
| JP2025502061A5 (https=) | ||
| US20250333522A1 (en) | Compositions and methods for treating pain in subjects with rheumatoid arthritis | |
| JP2025509567A5 (https=) | ||
| KR20240117655A (ko) | 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임 | |
| JP2025509567A (ja) | 再発性類上皮肉腫を、二重特異性抗ＭＵＣ１６ｘ 抗ＣＤ３抗体単独で、または抗ＰＤ－１抗体と組み合わせて治療する方法 | |
| JP2022520572A5 (https=) | ||
| CN118871128A (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| RU2024122332A (ru) | СПОСОБЫ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕГО РАКА ЯИЧНИКА С ПОМОЩЬЮ БИСПЕЦИФИЧНЫХ АНТИТЕЛ К MUC16 x CD3 ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С АНТИТЕЛАМИ К PD-1 | |
| RU2024129390A (ru) | СПОСОБЫ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕЙ ЭПИТЕЛИОИДНОЙ САРКОМЫ С ПОМОЩЬЮ БИСПЕЦИФИЧНЫХАНТИТЕЛ ПРОТИВ MUC16 x CD3 САМИХ ПО СЕБЕ ИЛИ В КОМБИНАЦИИ С АНТИТЕЛАМИ ПРОТИВ PD-1 | |
| US20220389088A1 (en) | Anti-angiopoietin-like 4 (angptl4) antibodies and methods of use | |
| CN116615238A (zh) | 用于治疗癌症和减轻细胞因子释放综合征的抗体组合 | |
| JP2025508832A5 (https=) | ||
| JP2021518393A5 (https=) | ||
| RU2022101756A (ru) | Антитела к tigit и их применение | |
| TH2101002581A (th) | วิธีการทรีตโรคตาโปนจากไทรอยด์โดยใช้แอนติบอดีชนิด anti-fcrn | |
| TW202608479A (zh) | 治療具有類風濕性關節炎的個體中疼痛之組成物及方法 |